Atlas Trials

Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer

Clinical trial NCT04093167 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04093167
Sponsor
Canadian Cancer Trials Group
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Lung Cancer
Start date
2020-05-26
Primary completion
2026-12-31
Enrollment
53

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.